Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight ...

Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...

The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...

Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...

The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23, 2023 ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...

The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.

A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...

Novo Nordisk is contesting Sen. Bernie Sanders' calls to reduce the list prices of Ozempic and Wegovy in the U.S., Bloomberg reports. In late April, the Senate Health, Education, Labor, and Pensions ...